Compare Heron Therapeutics Inc (HRTX) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs United Microelectronics Corp — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while United Microelectronics Corp trades at $22.9 (market cap $58.02B). The key difference: United Microelectronics Corp is far larger — about 853.1× Heron Therapeutics Inc's market cap, and United Microelectronics Corp pays a 1.76% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and United Microelectronics Corp for 42 Days on average.
| HRTX | UMC | |
|---|---|---|
Market Cap | $68.01M | $58.02B |
Volume | 1,891,941 | 11,897,809 |
Sector | Health | Technology |
52-Week High | $1.49 | $28.02 |
52-Week Low | $0.27 | $7.02 |
Typical Hold Time | 35 Days | 42 Days |
Enterprise Value | $174.75M | $55.10B |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
UMC trades at $22.92, down 1.67% on the day, with a bullish technical signal despite recent weakness. The company has delivered strong earnings beats in recent quarters, with Q2 2026 EPS of $0.54 significantly exceeding the $0.16 estimate. Revenue is projected to grow to $250.7 billion in 2026, with net income margin improving to 32.75%. Cash flow trends show a positive turnaround with 2025 net cash flow of $5.66 billion after two years of negative flows.
The outlook remains positive with strong profitability metrics and analyst upgrades, though competition and market volatility present risks. The stock appears fundamentally sound with improving cash generation and earnings momentum, supported by AI-driven semiconductor demand. Valuation metrics suggest reasonable pricing relative to growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
